Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Denali TherapeuticsBSP:D2NL34 6 PS Ratio is 273.33 as of Aug. 20, 2026, which is 507% above its 10-year median of 45.05. GuruFocus rates BSP:D2NL34 with a GF Score™ of 6/100. The stock has 6 warning signs investors should review. Among 931 Biotechnology companies, Denali Therapeutics ranks worse than 96.78% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Denali Therapeutics's share price is R$27.06.
Denali Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was R$0.10. Hence, Denali Therapeutics's PS Ratio for today is 273.33.
The historical rank and industry rank for Denali Therapeutics's PS Ratio or its related term are showing as below:
BSP:D2NL34'
s PS Ratio Range Over the Past 10 Years
Min: 6.67 Med: 45.05 Max: 3483.33
Current: 1352.11
During the past 11 years, Denali Therapeutics's highest PS Ratio was 3483.33. The lowest was 6.67. And the median was 45.05.
BSP:D2NL34's PS Ratio is ranked worse than 96.78% of 931
companies
in the Biotechnology industry
Industry Median: 9.56
vs BSP:D2NL34: 1352.11
During the past 11 years, Denali Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 45.80% per year. The lowest was -34.00% per year. And the median was -6.90% per year.
Denali Therapeutics (BSP:D2NL34) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Denali Therapeutics PS Ratio Related Terms
Denali Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Denali Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:D2NL34 vs RCUS, ALMS, ELVN: PS Ratio Comparison
For the Biotechnology subindustry, Denali Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Denali Therapeutics's Share Price of today is R$27.06. Denali Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0.10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Denali Therapeutics (BSP:D2NL34) has a PS Ratio of 273.33 as of Aug. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Denali Therapeutics and its competitors. This is 507% above median its historical median of 45.05. Over the past decade, Denali Therapeutics' PS Ratio has ranged from 6.67 to 3,483.33. According to the industry distribution chart, Denali Therapeutics ranks #901 out of 931 companies in the Biotechnology industry, placing it in the top 96.8%.
Is Denali Therapeutics' PS Ratio too high?
Denali Therapeutics' current PS Ratio of 273.33 is 507% above median its 10-year median of 45.05. Over the past 10 years, this metric has ranged from a low of 6.67 to a high of 3,483.33. The Biotechnology industry median PS Ratio is 9.56. Denali Therapeutics' value of 273.33 is 2759.1% above this industry median. Based on the distribution chart, Denali Therapeutics ranks #901 out of 931 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Denali Therapeutics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' PS Ratio compare to RCUS and ALMS?
According to the Biotechnology industry distribution chart, Denali Therapeutics ranks #901 out of 931 companies for PS Ratio. This places Denali Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.56. Denali Therapeutics' value of 273.33 is 2759.1% above this benchmark. Historically, Denali Therapeutics' own PS Ratio has ranged from 6.67 to 3,483.33 over the past decade. While the company's 10-year median is 45.05 vs. the industry median of 9.56, Denali Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.56, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Denali Therapeutics's current PS Ratio of 273.33 is 2759.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Denali Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Denali Therapeutics's current PS Ratio is 273.33, which is 507% above median its own 10-year median of 45.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Denali Therapeutics (BSP:D2NL34) has a current PS Ratio of 273.33. The current PS Ratio is 273.33, which is 507% above median its 10-year median of 45.05 and 2759.1% above the Biotechnology industry median of 9.56. Denali Therapeutics' overall GF Score™ is 6/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Denali Therapeutics (BSP:D2NL34), the current PS Ratio is 273.33 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
6GF Score
Get the complete analysis for BSP:D2NL34
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:D2NL34 has been successfully added to your 
